[{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"85b0714e-dfbe-462f-9e1b-b16f61823ed6","acronym":"EPIcol","url":"https://clinicaltrials.gov/study/NCT06147960","created_at":"2023-11-28T20:16:44.810Z","updated_at":"2024-07-02T16:35:27.930Z","phase":"","brief_title":"Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer","source_id_and_acronym":"NCT06147960 - EPIcol","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" BIRC3 • XIAP","pipe":"","alterations":" ","tags":["BIRC3 • XIAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-11-28"},{"id":"94fe4903-a2c9-42e8-862b-770fa6d33088","acronym":"I-HEP","url":"https://clinicaltrials.gov/study/NCT04810156","created_at":"2021-03-22T11:52:24.698Z","updated_at":"2025-02-25T14:02:17.911Z","phase":"Phase 2","brief_title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","source_id_and_acronym":"NCT04810156 - I-HEP","lead_sponsor":"Inge Marie Svane","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prednisone • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/07/2025","primary_completion_date":" 04/07/2025","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2022-12-14"},{"id":"5c81a4de-97be-4d18-8c2e-fddbafac6d68","acronym":"INVINCIBLE","url":"https://clinicaltrials.gov/study/NCT04781725","created_at":"2021-03-04T12:52:17.514Z","updated_at":"2024-07-02T16:36:20.608Z","phase":"Phase 2","brief_title":"INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer","source_id_and_acronym":"NCT04781725 - INVINCIBLE","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-11-17"},{"id":"382f094f-2c2c-4bea-884f-f64a47d2d877","acronym":"","url":"https://clinicaltrials.gov/study/NCT01097304","created_at":"2021-01-18T04:20:21.441Z","updated_at":"2025-02-25T13:59:48.726Z","phase":"Phase 2","brief_title":"Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia","source_id_and_acronym":"NCT01097304","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MKI67","pipe":"","alterations":" ","tags":["MKI67"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2017-12-19"},{"id":"398de438-177f-4245-b03c-2ec81312578c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02715882","created_at":"2021-01-18T13:16:56.079Z","updated_at":"2024-07-02T16:37:25.815Z","phase":"Phase 2","brief_title":"Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer","source_id_and_acronym":"NCT02715882","lead_sponsor":"BioLab 612 LLC","biomarkers":" IL6 • CXCL8 • IL10","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e entolimod (STAT-600)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 12/31/2017","study_completion_date":" 12/31/2017","last_update_posted":"2017-02-09"}]